RemeGen, Ltd. develops and manufactures medicines for cancer, autoimmune, and eye diseases. The company offers products for rheumatoid arthritis, neuromyelitis optica spectrum disorder, system lupus erythematosus, multiple scierosis, IgA nephritis, gravis, sjogren’s syndrome, gastric cancer, urothelial cancer, breast cancer, lung cancer, bile duct cancer, wAMD, diabetic macular edema, and multiple solid cancer diseases. The company was founded in 2008 and is based in Yantai, China. RemeGen, Ltd. operates as a subsidiary of Rongchang Pharmaceutical Co., Ltd.